Delaware Clinical and Translational Research ACCEL Program

特拉华州临床和转化研究 ACCEL 计划

基本信息

批准号：
10885455
负责人：
Gregory E Hicks
金额：
$ 20.91万
依托单位：
UNIVERSITY OF DELAWARE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-25 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10885455
关键词：
Acceleration Adult African American Agreement American Area Asian Award Biometry Black race Budgets Caucasians Cessation of life Child Health Childhood Clinical Clinical Research Communities Community Outreach Delaware Development Epidemiology Equity Ethnic Origin Evaluation Funding Goals Grant Growth Health Health Promotion Healthcare Healthcare Systems Hispanic Hospitals Infrastructure Institution Intention Investments Learning Letters Malignant Neoplasms Mission Modeling Modification Native Americans Obesity Outreach Research Pharmaceutical Preparations Pilot Projects Population Population Heterogeneity Population Research Recommendation Research Design Research Personnel Rural Scientist Societies Structure System Time Training Translational Research Universities Work Writing clinical infrastructure community engagement design health care quality health equity health inequalities hospitalization rates improved innovation member multiple chronic conditions population health programs racial diversity recruit translational research program translational scientist

项目摘要

ABSTRACT- OVERALL This proposal is a competitive renewal of the Institutional Development Award Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013 to the University of Delaware. The ACCEL CTR Program, has completed nine years of funding at the time of this application. During our third funding cycle (ACCEL3), our consortium will consist of four partners: University of Delaware (UD)—the lead institution; Nemours Children’s Health (Nemours); Christiana Care Health System (CCHS), the largest health care system in Delaware; and Delaware State University (DSU), an American historically Black, public university that joined our consortium during the last competitive renewal. Over the past nine years, ACCEL has established an exceedingly strong network and infrastructure for clinical and translational (C&T) research within the state of Delaware; and, we are now poised and ready to continue our growth trajectory. While we will continue with the activities that have made us successful, we will have a sharper focus on building sustainable infrastructure across the state that can continue to thrive and mature for years to come. And, we will focus on creating a scientific culture focused, not only, on improving the health of Delawareans, but doing so through a lens of health equity. In our mission to establish a cadre of successful C&T scientists in DE, we will use various approaches to promote full consideration of how their work impacts the needs of all members of society, from design to study implementation to dissemination of findings. And, we will have a much greater focus on building a bi-directional relationship between our scientists and the community so that we can have a greater impact on Delawareans. Delaware is an ideal state for a CTR grant as it represents the whole of the USA in a compact form. The population of Delaware (~970,000) mirrors the US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 23% African American, 62% Caucasian, 10% Hispanic, 4% Asian and 1% Native American. Thus, studies involving a cross-section of Delaware can be generalizable to populations nationally. The dominance of adult (CCHS) and pediatric (Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact population health. The overarching goal of the ACCEL CTR Program is to create a unified Delaware Clinical and Translational Research Community (inclusive of investigators and community members) that breaks down existing barriers, capitalizes on the unique strengths of its partners to establish infrastructure and accelerates the creation of equitable solutions that improve the health of all Delawareans and all Americans.

摘要-总体该提案是对机构发展奖计划基础设施的竞争性更新临床和转化研究 (IDeA-CTR)(U54) 拨款最初于 2013 年 9 月授予特拉华大学的 ACCEL CTR 项目截至 2017 年已完成九年的资助。在我们的第三个融资周期（ACCEL3）中，我们的联盟将由四个合作伙伴组成：特拉华大学 (UD)——内穆尔儿童健康中心 (Nemours Christiana)；护理医疗系统 (CCHS)，特拉华州最大的医疗保健系统和特拉华州立大学；（DSU），一所美国历史悠久的黑人公立大学，去年加入我们的联盟在过去的九年里，ACCEL 建立了一个极其强大的网络。特拉华州内的临床和转化 (C&T) 研究基础设施；现在我们已经准备好继续我们的增长轨迹，同时我们将继续开展这些活动。使我们取得了成功，我们将更加专注于在各地建设可持续的基础设施而且，我们将致力于创建一个能够在未来几年继续繁荣和成熟的国家。科学文化不仅注重改善特拉华州人的健康，而且还通过镜头来实现这一目标为了在 DE 建立一支成功的 C&T 科学家队伍，我们将使用健康公平的理念。采取各种方法来促进充分考虑其工作如何影响所有成员的需求社会，从设计到研究实施再到研究结果的传播，我们将会有很多。更加注重在我们的科学家和社区之间建立双向关系，以便我们可以对特拉华州人产生更大的影响，因为它是 CTR 补助金的理想州。特拉华州的人口（约 970,000）反映了整个美国的紧凑形式。美国人口的城乡公民比例和民族/种族多样性，其中 23% 为非裔美国人，62% 白种人、10% 西班牙裔、4% 亚洲人和 1% 美洲原住民因此，研究涉及不同群体。特拉华州可以推广到全国范围内的成人 (CCHS) 和儿童的主导地位。 (内穆尔) 医院系统为该州至少 85% 的居民提供服务，提供了独特的服务有机会将特拉华州作为研究医疗保健变化如何影响的模型 ACCEL CTR 计划的总体目标是创建一个统一的特拉华州。临床和转化研究社区（包括研究者和社区成员）打破现有壁垒，利用合作伙伴的独特优势，建立基础设施并加速创建公平的解决方案，以改善所有人的健康特拉华州人和所有美国人。

项目成果

期刊论文数量（287）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Comprehensive pain management strategy for infants with moderate to severe osteogenesis imperfecta in the perinatal period.

DOI：
10.1002/pne2.12066
发表时间：
2021-12
期刊：
Paediatric & neonatal pain
影响因子：
0
作者：
Carroll RS;Donenfeld P;McGreal C;Franzone JM;Kruse RW;Preedy C;Costa J;Dirnberger DR;Bober MB
通讯作者：
Bober MB

Disparities in Delaware Caregiver Beliefs about the COVID-19 Vaccine for their Children.